MUC16 and breast cancer: According to estrogen antagonism of tamoxifen therapy, the mammary tumor marker CA15.3 and general tumor marker CEA significantly decreased in carcinogenic mice, but CA125 significantly decreased in carcinogenic mice due to its potentiality on inhibition of progesterone receptors in the endometrium60,61.